drug
deucravacitinib
Marketedupdated 6mo agoby Bristol-Myers Squibb Co
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
Trials studying deucravacitinib
- —Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
- —A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
- phase3Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- phase3A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- phase3A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
- phase3A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- phase3A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
- phase3A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 9, 2027
296 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Feb 11, 2043formulationUS 12521390
- Nov 7, 2033compositionUS 10000480
- Nov 7, 2033method-of-use (U-3434)US 11021475
- Nov 7, 2033compositionUS RE47929
FDA exclusivities (1)
- Sep 9, 2027NCENew Chemical Entity (5y)296d
News(10)
- China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis winA phase 3 trial of InventisBio’s nomelcitinib has hit its primary endpoint, delivering evidence that the TYK2 inhibitor can hold its own against rival psoriasis drugs.fiercebiotech · 15d ago
- 5 new drug launches that defied industry expectationsA clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.biospace · 20d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 1mo ago
- Amgen reports a Phase 3 win with Sjögren’s drug candidateDazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.biopharma_dive · 1mo ago
- Alumis’ TYK2 drug fails in key lupus studyThough Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.biopharma_dive · 2mo ago
- Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunityThe approval of rusfertide—now to be branded Mimrylo—for polycythemia vera marks a key win for Takeda, which now has crossed the FDA finish line for two of three critical product launches slated fo…biospace · 2mo ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 3mo ago
- InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis testInnoCare Pharma announced Monday that its oral tyrosine kinase 2 (TYK2) inhibitor fadeucravacitinib met the primary endpoint in a phase 3 trial of adults with moderate-to-severe plaque psoriasis.fiercebiotech · 3mo ago
- Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 updateTakeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.fiercebiotech · 4mo ago
- Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialA phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.fiercebiotech · 4mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that